Phase 3 ALS study (CY 5031) with reldesemtiv. (Cytokinetics)

This is a Phase 3, double-blind, randomized, placebo-controlled trial of reldesemtiv in patients aged 18 to 80 with ALS to assess the effect of reldesemtiv versus placebo on functional outcomes in ALS

Sponsor(s)
Cytokinetics
Principal Investigator(s)
Dr. Elham Bayat
Contact Phone Number
Request Information
Address

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

11 + 7 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.